Phase III clinical trial results published in NEJM. LITESPARK-005 supports FDA approval of belzutifan for patients with advanced #kidneycancer. Research led by Toni Choueiri, MD #RCC Read more: ms.spr.ly/6011lxfKL cc: Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

In participants with advanced renal-cell carcinoma, belzutifan, a HIF-2α inhibitor, was superior to everolimus, an mTOR inhibitor, with respect to progression-free survival and tumor response. Read the full LITESPARK-005 trial results: nej.md/4cvmO2R

At the dame time please don’t forget to register in a football championship! Read my post!! x.com/cdanicas/statu…

Happening ! The ESMO - Eur. Oncology #ESMO24 Soccer ⚽️ Futbol tournament !

After receiving a #KidneyCancer diagnosis, your doctors will determine the stage of your cancer in order to guide treatment decisions. Learn more and explore other valuable resources in our Patient Resource Center. 🔗kidneycan.org #AcceleratingCures

GU Research Digest for the week of August 17 - 23: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

Liquid biopsy in renal cell carcinoma | The Oncologist | with Marc Machaalani Karl Semaan, MD, MSc Marc Eid Rashad Nawfal, MD Razane El Hajj Chehade Sylvan Baca MD PhD (Hiring!) from Dana-Farber Lank Center for Genitourinary Oncology academic.oup.com/oncolo/advance…

Very important task force led by Debra Patt --a Must read! ASCO

Congrats to our own joaquim bellmunt who leads the bladder cancer efforts Dana-Farber Lank Center for Genitourinary Oncology OncoAlert ESMO Open ESMO - Eur. Oncology

A very important and practice-informing trial dealing with HIF2 inhibitor Belzutifan dose in RCC. More is not better ! Congrats Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute and team! Bravo !

Thank you TIME for highlighting our work in Kidney Cancer at Dana-Farber and Dana-Farber Lank Center for Genitourinary Oncology time.com/7018184/kidney…

Out today in TIME — a review of recent advances in #KidneyCancer treatment highlighting the incredible work of Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Brian Rini, MD Vanderbilt Hem / Onc william huang nyulmc Katie Spina (she/her) Columbia RadOnc George R Schade Fred Hutchinson Cancer Center and many others! It takes a village to

A beautiful night celebrating our friend/collaborator and scientist-extraordinaire Matt Freedman, the new David Goldstein Chair Dana-Farber. The Chair will focus on many aspects of Kidney Cancer Research Dana-Farber Lank Center for Genitourinary Oncology